ADMA Biologics, Inc. (NASDAQ:ADMA) is the Best Russell 2000 Stock.
On May 6, 2026, ADMA Biologics, Inc. (NASDAQ:ADMA) reported Q1 revenue of $114.5 million, flat YoY. The company delivered adjusted net income of $40.7 million with 22% growth and adjusted EBITDA of $59.7 million, jumping 24%, the company said. Cash generation held firm, with operating cash flow reaching $58 million. Nonetheless, CEO Adam Grossman called it “near-term topline pressures” from competitive dynamics and distributor ordering variability impacting BIVIGAM.
ASCENIV revenue climbed 28% year over year with “record utilization growth,” Grossman said, while BIVIGAM revenue fell 54%, showing shifting inventory behavior rather than weakening demand. Margins expanded, gross margin hit 71%, and management framed the quarter as a trough baseline.
Pixabay/Public Domain
ADMA Biologics, Inc. (NASDAQ:ADMA) forecasts revenue to be $530 million to $560 million in 2026 and adjusted EBITDA of $265 million to reach $300 million. However, it has withdrawn long-term guidance due to changing market conditions.
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that makes specialty biologics made from plasma. The company operates in ADMA BioManufacturing and Plasma Collection Center segments.
While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
